Phototoxicity of flavoprotein miniSOG induced by bioluminescence resonance energy transfer in genetically encoded system NanoLuc-miniSOG is comparable with its LED-excited phototoxicity

Прошкина, Г. М.; Шрамова, Е. И.; Shilova, O N; Ryabova, A. V.; Deyev, Sergey M.

doi:10.1016/j.jphotobiol.2018.09.006

Cited by 31 publications

(41 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For tumor generation mice were inoculated subcutaneously with 2 × 10 6 cells BT-474 stably expressing NanoLuc luciferase gene [ 51 ]. Inoculation of cancer cells was performed in 30% Matrigel (Corning, NY, USA) in culture medium.…”

Section: Methodsmentioning

confidence: 99%

Dual Targeting of Cancer Cells with DARPin-Based Toxins for Overcoming Tumor Escape

Шрамова

Прошкина

Shipunova

et al. 2020

Cancers

View full text Add to dashboard Cite

We report here a combined anti-cancer therapy directed toward HER2 and EpCAM, common tumor-associated antigens of breast cancer cells. The combined therapeutic effect is achieved owing to two highly toxic proteins – a low immunogenic variant of Pseudomonas aeruginosa exotoxin A and ribonuclease Barnase from Bacillus amyloliquefaciens. The delivery of toxins to cancer cells was carried out by targeting designed ankyrin repeat proteins (DARPins). We have shown that both target agents efficiently accumulate in the tumor. Simultaneous treatment of breast carcinoma-bearing mice with anti-EpCAM fusion toxin based on LoPE and HER2-specific liposomes loaded with Barnase leads to concurrent elimination of primary tumor and metastases. Monotherapy with anti-HER2- or anti-EpCAM-toxins did not produce a comparable effect on metastases. The proposed approach can be considered as a promising strategy for significant improvement of cancer therapy.

show abstract

Section: Methodsmentioning

confidence: 99%

Dual Targeting of Cancer Cells with DARPin-Based Toxins for Overcoming Tumor Escape

Шрамова

Прошкина

Shipunova

et al. 2020

Cancers

View full text Add to dashboard Cite

show abstract

“…This involves imaging the expression of the therapeutic gene after it has been transferred to evaluate the efficiency of the treatment [13], [113]. Several studies in gene therapy have been conducted to monitor tumor phenomena using BLI including the imaging of metastasis [114], apoptosis [115], [116], tumor hypoxia [117]- [122], and angiogenesis [123].…”

Section: Dmentioning

confidence: 99%

Bioluminescence Imaging Applications in Cancer: A Comprehensive Review

AlSawaftah

Farooq

Dhou

et al. 2021

IEEE Rev. Biomed. Eng.

View full text Add to dashboard Cite

Bioluminescence imaging (BLI), an optical preclinical imaging modality, is an invaluable imaging modality due to its low-cost, high throughput, fast acquisition times, and functional imaging capabilities. BLI is being extensively used in the field of cancer imaging, especially with the recent developments in geneticengineering, stem cell, and gene therapy treatments. The purpose of this paper is to provide a comprehensive review of the principles, developments, and current status of BLI in cancer research. This paper covers the fundamental BLI concepts including BLI reporters and enzyme-substrate systems, data acquisition, and image characteristics. It reviews the studies discussing the use of BLI in cancer research such as imaging tumor-characteristic phenomena including tumorigenesis, metastasis, cancer metabolism, apoptosis, hypoxia, and angiogenesis, and response to cancer therapy treatments including chemotherapy, radiotherapy, immunotherapy, gene therapy, and stem cell therapy. The key advantages and disadvantages of BLI compared to other common imaging modalities are also discussed.

show abstract

“…A recent report describes that cell death can be mediated by the action of luciferase on the flavin-containing protein miniSOG (Proshkina et al, 2018), suggesting that luciferase-catalyzed uncaging of asLOV2 may also be possible. To explore this possibility, we considered the range of luciferases used for biological research; these include Vargula hilgendorfii (VLuc ( Stacer et al, 2013)).…”

Section: Selection Of Nanoluc As the Luciferase Donor For Lovmentioning

confidence: 99%

Luciferase-LOV BRET enables versatile and specific transcriptional readout of cellular protein-protein interactions

Kim

Cho

Kim

et al. 2019

Preprint

View full text Add to dashboard Cite

Technologies that convert transient protein-protein interactions (PPIs) into stable expression of a reporter gene are useful for genetic selections, high-throughput screening, and multiplexing with omics technologies. We previously reported SPARK (Kim et al., 2017), a transcription factor that is activated by the coincidence of blue light and a PPI. Here, we report an improved, second-generation SPARK2 that incorporates a luciferase moiety to control the light-sensitive LOV domain. SPARK2 can be temporally gated by either external light or addition of a small-molecule luciferin, which causes luciferase to open LOV via proximity-dependent BRET. Furthermore, the nested "AND" gate design of SPARK2-in which both protease recruitment to the membrane-anchored transcription factor and LOV domain opening are regulated by the PPI of interest-yields a lowerbackground system and improved PPI specificity. We apply SPARK2 to high-throughput screening for GPCR agonists and for the detection of trans-cellular contacts, all with versatile transcriptional readout.

show abstract

Phototoxicity of flavoprotein miniSOG induced by bioluminescence resonance energy transfer in genetically encoded system NanoLuc-miniSOG is comparable with its LED-excited phototoxicity

Cited by 31 publications

References 50 publications

Dual Targeting of Cancer Cells with DARPin-Based Toxins for Overcoming Tumor Escape

Dual Targeting of Cancer Cells with DARPin-Based Toxins for Overcoming Tumor Escape

Bioluminescence Imaging Applications in Cancer: A Comprehensive Review

Luciferase-LOV BRET enables versatile and specific transcriptional readout of cellular protein-protein interactions

Contact Info

Product

Resources

About